Dr John Byrd presents at an ASH 2012 press conference on the Bruton’s tyrosine kinase inhibitor ibrutinib (PCI-32765) which promotes high response rate, durable remissions, and is tolerable in treatment naïve and relapsed or refractory chronic lymphocytic leukaemia or small lymphocytic lymphoma patients including those with high-risk disease.